[ET Net News Agency, 24 August 2021] Credit Suisse lowered its target price for
Sinopharm (01099) to HK$26 from HK$29 and maintained its "outperform" rating.
The research house said downside risks include larger impact from COVID-19 resurgence in
China and continuing pricing pressure from generic drug/medical device GPO. (RC)